54396 Federal Register / Vol. 70, No. 177 / Wednesday, September 14, 2005 / Notices 

Disubstituted Levendustin A Analogs 

(Including Adaphostin) and 

Pharmaceutical Compositions 

Comprising the Analogs 

Venkatacha L. Narayanan et al. (NCI) 

U.S. Patent Application No. 09/623,000 

filed 25 Aug 2000 (DHHS Reference 

No. E–013–1998/0–US–07) 

Licensing Contact: John Stansberry; 

(301) 435–5236; 

stansbej@mail.nih.gov. 

Chronic myelogenous leukemia (CML) 

is almost universally associated with a 

translocation that juxtaposes the Bcr 

and Abl genes. Because the resulting 

kinase, p210 Brc/Abl, is found exclusively 

in malignant hematopoietic cells there 

has been considerable interest in 

identifying inhibitors of this enzyme. 

Adaphostin induces cytotoxicity in 

human leukemia cells by downregulating p210 Bcr/Abl, inducing DNA 

damage and initiating apoptosis. 

Adaphostin exhibits selectivity for CML 

myeloid progenitors in vitro and 

retained its catholicity when 

cytotoxicity mesylate-resistant K562 

cells were examined. Adaphostin may 

kill a wide range of human leukemia 

cells and may be effective against other 

cancer types. The present invention 

provides pharmaceutical compositions 

comprising effective amounts of 

adaphostin. The compound and 

composition of the present invention 

may be used for treating human 

leukemia and other proliferative 

diseases. 

In addition to licensing, the 

technology is available for further 

development through collaborative 

research opportunities with the 

inventors. 

Heterologous Boosting Immunizations 

Ronald S. Chamberlain et al. (NCI) 

U.S. Patent Application No. 09/171,086 

filed 22 Jan 1999 (HHS Reference No. 

E–087–1996/0-US–04); U.S. Patent 

Application No. 09/838,987 filed 20 

Apr 2001 (HHS Reference No. E–087–

1996/0–US–05); U.S. Patent 

Application No. 11/007,115 filed 08 

Dec 2004 (HHS Reference No. E–087–

1996/0–US–06); PCT Application No. 

PCT/US97/06632 filed 21 Apr 1997, 

which published as WO 97/39771 on 

30 Oct 1997 (HHS Reference No. E–

087–1996/0–PCT–02); and Canadian 

Patent Application Serial No. 

2,252,406 (HHS Reference No. E–087–

1996/0–CA–03) 

Licensing Contact: Michelle A. Booden; 

301/451–7337; 

boodenm@mail.nih.gov. 

The identification of tumor-associated 

antigens and the cloning of DNA 

sequences encoding them have enabled 

the development of anticancer vaccines. 

Such vaccines target tumors by 

stimulating an immune response against 

the antigens. One method of vaccination 

involves the delivery of antigenencoding DNA sequences, and a number 

of recombinant vectors have been used 

for this purpose. To optimize the 

efficacy of recombinant vaccines, Dr. 

Steve Rosenberg and colleagues at the 

NCI have developed treatment regimens 

that use two different vectors (i.e., 

heterologous boosting). 

The present invention describes the 

method of heterologous boosting 

immunizations, which in essence is the 

use of a priming vaccination and a 

boosting vaccination using two different 

recombinant vectors that contain a 

similar or different tumor associated 

antigen (TAA). The use of different 

recombinant vectors unexpectedly 

increases and maintains the immune 

response to most tumor-associated 

antigens included in the vectors. The 

claims are directed, but not limited to, 

various recombinant viral vectors: 

poxvirus, vaccine, adenovirus, etc. 

Additional embodiments and claims are 

directed, but not limited to, melanoma 

tumor antigens such as Mart1, gp100, or 

Hep B surface antigen. These tumor 

antigen expressing recombinant vectors 

are coupled with distinctly different 

recombinant vectors, which express 

various cytokines and co-stimulatory 

and accessory molecules such as B7–1, 

B7–2, ICAM–1, etc. This therapeutic 

intervention could be directed toward 

multiple human carcinomas but, with 

respect to this technology, has been 

customized as a therapeutic 

intervention for melanoma. 

This technology is available under an 

exclusive or non-exclusive license. In 

addition to licensing, the technology is 

available for further development 

through collaborative research 

opportunities with the inventors. 

Dated: September 2, 2005. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 05–18168 Filed 9–13–05; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Alternative Medicine; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel, Clinical Science. 

Date: October 20–21, 2005. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Park Hotel, 8400 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Jeanette M. Hosseini, 

Scientific Review Administrator, National 

Center For Complementary and Alternative 

Medicine, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, 301–594–9096. 

Dated: September 6, 2005. 

Anthony M. Coelho, Jr., 

Acting Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 05–18171 Filed 9–13–05; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. appendix 2), notice 

is hereby given of the tenth and final 

meeting of the Commission on Systemic 

Interoperability. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The mission of the Commission on 

Systemic Interoperability is to submit a 

report to the Secretary of Health and 

Human Services and to Congress on a 

comprehensive strategy for the adoption 

and implementation of health care 

information technology standards that 

includes a timeline and prioritization 

for such adoption and implementation. 

In developing that strategy, the